Aubagio teriflunomide regulatory update

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that Aubagio teriflunomide from the Genzyme Corp. unit of Sanofi has "no additional benefit" vs. interferon beta-1a to treat relapsing-remitting multiple sclerosis (RRMS). The assessment is in line with a January preliminary assessment from Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) (see BioCentury, Jan. 6). ...